MacroGenics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MacroGenics, Inc. (Nasdaq: MGNX) announced its participation in two investor conferences in January 2021. The first event is the H.C. Wainwright & Co. BioConnect 2021 Conference, featuring an on-demand corporate overview and a panel discussion on Precision Medicine with CEO Scott Koenig on January 13 at noon ET. The second event is the 39th Annual J.P. Morgan Healthcare Conference on January 14 at 10:00 AM ET, where MacroGenics will provide a corporate overview and engage in one-on-one meetings. Webcasts of the presentations will be available on the company’s website.

ROCKVILLE, MD, Jan. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in January:

• H.C. Wainwright & Co. BioConnect 2021 Conference. A corporate overview provided by MacroGenics’ management will be available for on-demand viewing from January 11 - 14, 2021. In addition, MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a panel discussion on Precision Medicine hosted by Scott Gottlieb, M.D., Former Commissioner of the U.S. Food and Drug Administration. The panel will cover the importance of biomarkers and cytogenetic profiling in drug discovery, development and commercialization and will take place on Wednesday, January 13, 2021, at noon ET.
• 39th Annual J.P. Morgan Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on January 14, 2021 at 10:00 AM ET.

Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.

About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

FAQ

What investor conferences is MacroGenics participating in January 2021?

MacroGenics is participating in the H.C. Wainwright & Co. BioConnect 2021 Conference and the 39th Annual J.P. Morgan Healthcare Conference.

When is the H.C. Wainwright & Co. BioConnect 2021 Conference?

The H.C. Wainwright & Co. BioConnect 2021 Conference will provide an overview from January 11-14, 2021.

What is the focus of the panel discussion featuring MacroGenics' CEO?

The panel discussion led by CEO Scott Koenig will focus on Precision Medicine and the role of biomarkers in drug development.

When will MacroGenics provide a corporate overview at the J.P. Morgan Healthcare Conference?

MacroGenics will provide its corporate overview on January 14, 2021, at 10:00 AM ET.

Where can I access the webcasts of MacroGenics' presentations?

Webcasts can be accessed in the Investor Relations section of MacroGenics' website under 'Events & Presentations.'